Literature DB >> 22735406

FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials.

Mike Mitka.   

Abstract

Mesh：

Year:  2012        PMID： 22735406     DOI： 10.1001/jama.2012.6684

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Subversive subjects: rule-breaking and deception in clinical trials.

Authors:  Rebecca Dresser
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

2.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Authors:  Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

3.  Group- versus Parent-Involvement CBT for Childhood Anxiety Disorders: Treatment Specificity and Long-term Recovery Mediation.

Authors:  Wendy K Silverman; Carla E Marin; Yasmin Rey; William M Kurtines; James Jaccard; Jeremy W Pettit
Journal:  Clin Psychol Sci       Date:  2019-03-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.